An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
The purpose of this study is to evaluate the effectiveness and safety of lenvatinib in patients who have anaplastic thyroid cancer.
1. Confirmed diagnosis of anaplastic thyroid cancer (ATC).
2. Must have adequately controlled blood pressure (less than or equal to 140/90).
3. Must have sufficient performance status and bone marrow function.
Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment will last approximately 6 months or longer. If you are still receiving study treatment at the time the study ends, you may continue taking commercially available lenvatinib. Also, until the study ends, you or your family will be contacted by telephone or e-mail about every 3 months after your last dose of study drug to find out how you are doing overall, whether your cancer has worsened, and what anticancer medications you may be taking.
Knight Clinical Trials Information Line